Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gamida Cell Ltd. - Ordinary Shares (NQ:GMDA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gamida Cell Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
From Gamida Cell Ltd.
Via Business Wire
Flotek Industries, Clear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones jumped by more than 800 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
From Gamida Cell Ltd.
Via Business Wire
Recap: Gamida Cell Q2 Earnings
  Gamida Cell (NASDAQ:GMDA) reported its Q2 earnings results on Monday, August 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning. 
Via InvestorPlace
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket
Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday. 
Via Benzinga
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
From Gamida Cell
Via Business Wire
Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Launch of Public Offering of Ordinary Shares
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
From Gamida Cell Ltd.
Via Business Wire
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. 
Via Benzinga
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results. 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
FDA Accepts Gamida's Filing For Stem Cell Transplant Candidate Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted for filing the Gamida Cell’s (NASDAQ: GMDA) Biologics License Application (BLA) for omidubicel in the treatment of patients with blood cancers... 
Via Benzinga
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
From Gamida Cell Ltd.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 61 companies made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 100 companies reached new 52-week lows. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning. 
Via InvestorPlace
27 Stocks Moving in Thursday's Pre-Market Session
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO. 
Via Benzinga
Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors
From Gamida Cell
Via Business Wire
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
From Gamida Cell Ltd.
Via Business Wire
Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
From Gamida Cell Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.